ADAPTIVE BIOTECHNOLOGIES (ADPT)

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 709 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. The company has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. The company comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Company Info

ADAPTIVE BIOTECHNOLOGIES

1165 Eastlake Ave E

Seattle WASHINGTON 98102

P: 12066590067

CEO: Chad Robins

Employees: 709

Website: https://www.adaptivebiotech.com